SHANGHAI, China, January 12, 2026 – Oricell Therapeutics Holdings Limited (“Oricell” or “the Company”), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing.
Shanghai, China, September 10, 2025 -- Oricell Therapeutics ("Oricell"), a clinical-stage biotech company at the forefront of oncology immunotherapy and advanced cell therapy development, today announced that Dr. Peter He, Oricell's co-founder and chief scientific officer, presented Oricell's proprietary technology platform, pipeline progress, global footprint, and strategic vision at the Morgan Stanley 23rd Annual Global Healthcare Conference taking place on September 8th-10th in New York City.
On August 21, 2025, the inaugural Evercore China Biotech Summit—hosted by leading global investment bank Evercore—wrapped up successfully in Shanghai, China. Oricell Therapeutics, a pioneer in China’s cell therapy sector, was the sole cell therapy firm invited to deliver a keynote at the summit. Dr. Peter He, Oricell’s co-founder and chief scientific officer, not only delivered an insightful presentation on the company’s cutting-edge technology platforms and pipeline advancements but also engaged in in-depth discussions with leading global specialists.
Shanghai, China & New Jersey, USA (December 6th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotech company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, today announced that it will present a poster on its novel multi-specific CAR-T therapy targeting BCMA, GPRC5D, and CD38 in heterogeneous multiple myeloma (MM) at the 2024 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA from December 7-10, 2024. This innovative therapy aims to address the challenges posed by antigen heterogeneity and the suppressive tumor microenvironment in extramedullary disease, ultimately improving clinical outcomes and durability for patients with relapsed/refractory (R/R) MM.
Shanghai, China & New Jersey, USA (November 11th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotech company dedicated to leading in oncology immunotherapy innovation and focusing on developing advanced cell therapies, announces details from Saturday’s oral presentation of its bispecific BCMAxGPRC5D CAR-T targeting heterogeneous multiple myeloma (MM), at the 39th Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) in Houston, TX. Additionally, the abstract has been selected for inclusion in the SITC Top 100 abstracts.
Shanghai, China & New Jersey, USA (November 5th, 2024) — Oricell Therapeutics (Oricell), a clinical-stage biotechnology company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, today announced an upcoming oral presentation for its bi-specific BCMAxGPRC5D CAR-T therapy targeting heterogeneous multiple myeloma (MM), at the 39th Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) being held at November 6-10, 2024 in Houston, TX., The pre-clinical studies on the dual CAR-T indicate its potential to address unmet medical needs in both newly diagnosed and relapsed/refractory MM patients.
Shanghai, China & New Jersey, USA (October 17th, 2024) — Oricell Therapeutics, a clinical-stage biotechnology company aiming to lead in oncology immunotherapy innovation and focusing on developing advanced cell therapies, announced the clearance of its investigational new drug (IND) application from China's National Medical Products Administration (NMPA) for its proprietary Dual AND Logic Claudin 18.2/Mesothelin (MSLN) autologous chimeric antigen receptor (CAR-T) therapy, OriC613. This approval grants Oricell the authority to initiate a Phase I clinical trial for advanced solid tumors, including gastric cancer, in China.
SHANGHAI, August 20th, 2024 — Oricell Therapeutics is pleased to announce the establishment of its Scientific Advisory Board (SAB) , which has been bolstered by the appointment of two esteemed experts in the field of multiple myeloma, Dr. Kenneth C. Anderson and Dr. Shaji Kumar. Such appointments strengthen Oricell’s global strategies of developing novel therapeutics especially its proprietary CAR-T products to combat malignancies, with a particular emphasis on the field of multiple myeloma(MM).
SHANGHAI, NEW JERSEY - July 15th, 2024 - Oricell Therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation (FTD) for OriCAR-017, a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). This designation is expected to accelerate the progress of clinical trials and the New Drug Application (NDA/BLA) review process. Prior to this, the FDA has granted Orphan Drug Designation (ODD) and has cleared an Investigational New Drug Application (IND) for OriCAR-017.
沪公网安备 31011502019994号